{"id":"W4311451997","doi":"10.1016/s2213-2600(22)00479-9","title":"PIONEER trial: favipiravir to treat moderate COVID-19","year":2022,"lang":"en","type":"letter","venue":"The Lancet Respiratory Medicine","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":false,"ca_institutions":"Western University","funders":"","keywords":"Favipiravir; Medicine; Coronavirus disease 2019 (COVID-19); Scopus; Ritonavir; Virology; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Clinical trial; Pandemic; Internal medicine; Traditional medicine; MEDLINE; Viral load; Virus; Antiretroviral therapy; Disease; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0101547,0.001181795,0.002396699,0.0006641928,0.001725806,0.003525715,0.002051448,0.03001458,0.01156003],"category_scores_gemma":[0.02578648,0.0007443517,0.001869192,0.0006620886,0.001951516,0.001997583,0.001128625,0.02081119,0.006885421],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.004443057,"about_ca_system_score_gemma":0.004253125,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004766171,"about_ca_topic_score_gemma":0.01278376,"domain_scores_codex":[0.9948284,0.002579484,0.0004653992,0.0004651882,0.001008066,0.000653533],"domain_scores_gemma":[0.9801491,0.01060971,0.001632448,0.0006227922,0.001951877,0.005034075],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.006386664,0.0001336671,0.0007204302,0.0004774763,0.0002397639,0.0007456043,0.00005378708,0.00008041146,0.0006476292,0.002577765,0.9583375,0.02959931],"study_design_scores_gemma":[0.0485509,0.002638723,0.005709141,0.002435846,0.000823664,0.0009776374,0.0001479536,0.0009513217,0.001034637,0.01066812,0.9259375,0.0001246403],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"editorial","genre_scores_codex":[0.002402577,0.01564961,0.0002194698,0.9149818,0.051599,0.0002221056,0.001323814,0.00007369289,0.01352787],"genre_scores_gemma":[0.01793169,0.005953691,0.0006861978,0.8780109,0.07386629,0.0003917283,0.0005607411,0.00006543179,0.02253338],"genre_candidate":"editorial","genre_consensus":null,"teacher_disagreement_score":0.03001458,"threshold_uncertainty_score":0.05370378,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2807573077795464,"score_gpt":0.4894685830130724,"score_spread":0.208711275233526,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}